Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.38 |
| ▸ | MMP13 | P45452 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 5/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125952 | 0.88 | SLC1A3 (0.39) | MMP9PPARGPPARAPPARDSRD5A2 | |
| SCHEMBL4596689 | 0.87 | TP53 (0.42) | PPARGPPARAPPARDCARM1PRMT6 | |
| SCHEMBL14003044 | 0.86 | HDAC6 (0.47) | PPARGPPARAEPHX2MAPK14 | |
| SCHEMBL4598180 | 0.85 | BRAF (0.38) | MMP9MMP13PPARGPPARAPPARD | |
| Hydrochloric Acid SCHEMBL4598799 | 0.85 | HDAC6 (0.46) | PPARGPPARAEPHX2MAPK14 | |
| SCHEMBL5128985 | 0.83 | PTPN1 (0.38) | PPARGPPARAPPARDEPHX2MAPK14 | |
| SCHEMBL4598564 | 0.82 | HDAC8 (0.55) | PPARGPPARAPPARD | |
| SCHEMBL5125574 | 0.80 | HDAC8 (0.49) | MMP13MAPK14 | |
| SCHEMBL4598174 | 0.78 | TDP1 (0.48) | MMP9MMP13MMP1MMP2 | |
| SCHEMBL4758324 | 0.78 | OPRM1 (0.45) | CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | BEXEL PHARMACEUTICALS. INC. | 2008-08-21 | — | — | US | claimed |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200521-A1 | Novel hydroxamic acid containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | MMP9 1292/4885MMP13 534/4885MMP1 305/4885 |
| US-20070004776-A1 | Novel hydroxamic acid-containing amino acid derivatives | HGFAC, HCAR2, BCAT1 | MMP9 1385/4885MMP13 639/4885MMP1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.